A Phase I, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of MEDI-575 in Patients With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Tovetumab (Primary)
- Indications Liver cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 05 Feb 2013 Planned End Date changed from 1 Feb 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 05 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.